Pharmacological chaperone therapy for Gaucher disease: A patent review

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 6, 2011, Pages 885-903

  Benito, Juan M ^a   García Fernández, José M ^a   Mellet, Carmen Ortiz ^b  

^a INSTITUTO DE INVESTIGACIONES QUÍMICAS   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

ambroxol; chemical chaperones; folding diseases; Gaucher disease; glucocerebrosidase; glycosidase inhibitors; iminosugars; isofagomine; lysosomal storage disorders; nojirimycin; pharmacological chaperone therapy

Indexed keywords

5 (3,5 DICHLOROPHENOXY) N (4 PYRIDINYL) 2 FURAMIDE; 5 (4 TOLYLTHIO)QUINAZOLINE 2,4 DIAMINE; 5 (ADAMANTYLAMINOCARBONYL)PENTYL DEOXYNOJIRIMYCIN; 5N, 6O N' OCTYLIMINOMETHYLIDENE NOJIRIMYCIN; AFEGOSTAT; AGALSIDASE BETA; ALKYL GLUCOIMIDAZOLE; AMBROXOL; BETA GLUCOCEREBROSIDASE; BETA GLUCOSEREBROSIDASE CHAPERONE; BETA GLUCOSIDASE; CALYSTEGINE B2; CHAPERONE; GLUCOSYLCERAMIDASE; GLYCOSIDASE INHIBITOR; HALO ISOFAGOMINE; HTS 02324; IMIGLUCERASE; IMINOSUGAR; MIGLUSTAT; MWP 01127; N DODECYL DEOXYNOJIRIMYCIN; N HEXADECYL AMINOINOSITOL; N NONYL DEOXYNOJIRIMYCIN; N NONYLDEOXYNOJIRIMYCIN; N OCTYL 2,5 ANHYDRO 2,5 IMINOGLUCITOL; N OCTYL BETA VALIENAMINE; N OCTYL ISOFAGOMINE; TALIGLUCERASE ALFA; UNCLASSIFIED DRUG; VELAGLUCERASE ALFA; VPRI;

BLOOD BRAIN BARRIER; CLINICAL TRIAL; ENZYME REPLACEMENT; ENZYME THERAPY; GAUCHER DISEASE; GENE MUTATION; GENE THERAPY; GENETIC VARIABILITY; HUMAN; LYSOSOME STORAGE DISEASE; NONHUMAN; PATENT; PHARMACOLOGICAL CHAPERONE THERAPY; PROTEIN FOLDING; REVIEW; STEM CELL TRANSPLANTATION; SUBSTRATE REDUCTION THERAPY;

BLOOD-BRAIN BARRIER; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME REPLACEMENT THERAPY; GAUCHER DISEASE; HUMANS; IMINO PYRANOSES; MOLECULAR CHAPERONES; PATENTS AS TOPIC; PROTEIN FOLDING;

EID: 79956208079     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.569162     Document Type: Review

References (138)

1. Barrange JA, Cabrera-Salazar MA. Lysosomal storage disorders. Springer, NY; 2007
2. Futerman AH, van Meer G. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 2004;5:554-65 (Pubitemid 38868584)
3. Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med 2009;1:268-79
4. Meikle PJ, Fietz MJ, Hopwood JJ. Diagnosis of lysosomal storage disorders: current techniques and future directions. Expert Rev Mol Diagn 2004;4:677-91 (Pubitemid 39220841)
5. Wennekes T, van den Berg RJBHN, Boot RG, et al. Glycosphingolipids- Nature, function, and pharmacological modulation. Angew Chem Int Ed 2009;48:8848-69
6. De Duve C, Pressman BC, Gianetto R, et al. Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem J 1955;60:604-17
7. Pastores GM. Enzyme therapy for the lysosomal storage disorders: principles, patents, practice and prospects. Expert Opin Ther Pat 2003;13:1157-72 (Pubitemid 36986938)
8. Smid BE, Aerts JMFG, Boot RG, et al. Pharmacological small molecules for the treatment of lysosomal storage disorders. Expert Opin Invest Drug 2010;19:1367-79
9. Bernier V, Lagace M, Bichet DG, Bouvier M. Pharmacological chaperones: potential treatment for conformational disease. Trends Endocrinol Metabol 2004;15:5
10. Coehn FE, Kelly JW. Therapeutic approaches to protein misfolding diseases. Nature 2003;426:905-9 (Pubitemid 38056884)
11. Grabowski GA, Kolodny EH, Weinreb NJ, et al. Gaucher disease: phenotypic and genetic variation, Chapter 146.1. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors, The metabolic and molecular bases of inherited disease. McGraw-Hill, NY;
12. Available from: http://genetics.accessmedicine.com [Last accessed 11th February 2011]
13. Kornfeld S. Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Ann Rev Biochem 1992;61:307-30
14. Krivit W. Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv Pediatr 2002;49:359-78
15. MacDermot KD, Holmes A, Miners AH. Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 2001;24:s13-14; discussion 11-2
16. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41:s4-s14
17. Gaucher PCE. De l?epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leucemie [academic thesis]. Paris, France; 1882
18. Beutler E, Grabowski GA. Glucosylceramide lipidosis-Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors, The metabolic and molecular bases of inherited diseases. 8th edition. McGraw-Hill, NY; p. 3635-68.
19. Zeller JL, Burke AE, Glass RM. Gaucher disease. JAMA 2007;298:1358 (Pubitemid 47443361)
20. Sidransky E. Gaucher disease: complexity in a "simple" disorder. Mol Genet Metab 2004;83:6-15 (Pubitemid 39311276)
21. Raghavan SS, Topol J, Kolodny EH. Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease. Am J Hum Genet 1980;32:158-73 (Pubitemid 10105547)
22. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher?s disease. Lancet 2008;372:1263-71
23. Beutler E, Gelbart T, Scott CR. Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 2005;35:355-64 (Pubitemid 41627801)
24. Hruska KS, LaMarca, ME, Sidransky E. Gaucher disease: molecular biology and genotype-phenotype correlations. In: Futerman AH, Zimran A, editors, Gaucher disease. Taylor & Francis, Boca Raton; 2006. p. 13-48
25. Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation polymorphism spectrum in the glucorebrosidase gene (GBA). Hum Mutat 2008;29:567-83 (Pubitemid 351614580)
26. Dvir H, Harel M, McCarthy AA, et al. X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep 2003;4:704-9 (Pubitemid 36974756)
27. Zuckerman S, Lahad A, Shmueli A, et al. Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases. JAMA 2007;298:1281-90 (Pubitemid 47443342)
28. Sobera LA, Sundaravinayagan D, Dulsat C, Rosa E. Therapeutic targets for Gaucher?s disease. Drug Future 2009;34:1001-4
29. Zimran A, Altarescu G, Phillips M, et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 2010;115:4651-6
30. Available from: www.news-medical.net/ news/20100712/FDA-accepts- Protalixstaliglucerase- alfa-NDA-assigns-PDUFAaction- date.aspx [Last accessed 11th Februrary 2011]
31. Biomarin pipeline: GALNS for MPS IVA (Morquio A disease). Available from: www.bmrn.com/pipeline/ morquio-syndrome.php [Last accessed 11th February 2011]
32. Shire pipeline. Available from: www. shire.com/shireplc/en/rd/pipeline [Last accessed 11th February 2011].
33. Platt FM, Jeyakumar M. Substrate reduction therapy. Acta Paediatr Suppl 2008;97:88-93 (Pubitemid 351421298)
34. Shukla GS, Shukla A, Radin NS. Gangliosides inhibit glucosylceramide synthase: a possible role in ganglioside therapy. J Neurochem 1991;56:2125-32
35. Platt FM, Jeyakumar M, Andersson U, et al. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis 2001;24:275-90 (Pubitemid 32479421)
36. Radin NS. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconjugate J 1996;13:153-7 (Pubitemid 26132722)
37. Schiffmann R, Fitzgibbon EJ, Harris C, et al. Randomized, controlled trial of miglustat in Gaucher?s disease type 3. Ann Neurol 2008;64:514-22
38. Cox T, Lachman R, Hollak C, et al. Novel oral treatment of Gaucher?s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481-5 (Pubitemid 30237353)
39. Platt FM, Butters TD, Barranger JA. Substrate reduction therapy. In: Barranger JA, Cabrera-Salazar MA, editors, Lysosomal storage disorders. Springer, NY; 2007. p. 153-68
40. Cabrera-Salazar MA, Novelli E, Barranger JA. Gene therapy for the lysosomal storage disorders. Curr Opin Mol Ther 2002;4:349-58 (Pubitemid 36305026)
41. Sands MS. Gene therapy. In: Platt FM, Walkley SU, editors, Lysosomal disorders of the brain. Oxford University Press, Oxford; 2004. p. 409-30
42. Snyder EY, Daley GQ, Goodell M. Taking stock and planning for the next decade: realistic prospects for stem cell therapies for the nervous system. J Neurosci Res 2004;76:157-68 (Pubitemid 38451203)
43. Lee JP, Clark D, Jeyakumar M, et al. Neural stem cell therapy in lysosomal storage disorders. In: Barrange JA, Cabrera-Salazar MA, editors, Lysosomal storage disorders. Springer, NY; 2007. p. 197-216
44. Ringden O, Groth CG, Erikson A, et al. Ten years? experience of bone marrow transplantation for Gaucher disease. Transplantation 1995;59:864-70
45. Pollack A. FDA halts 27 gene therapy trials after illness: leukemia-like cases in 2 children in France prompt the action. NY Times (print) 2003:A1, 17
46. Marshall E. Gene therapy. Second child in French trial is found to have leukemia. Science 2003;299:320 (Pubitemid 36120006)
47. Bonetta L. Leukemia case triggers tighter gene-therapy controls. Nat Med 2002;8:1189 (Pubitemid 35373536)
48. Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1999;5:112-15 (Pubitemid 29051008)
49. Fan JQ. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Biol Chem 2007;389:1-11
50. Suzuki Y, Ichinomiya S, Kurosawa M, et al. Chemical chaperone therapy: clinical effect in murine GM1-gangliosidosis. Ann Neurol 2007;62:671-5
51. Fan JQ, Ishii S. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. FEBS J 2007;274:4962-71 (Pubitemid 47481192)
52. Porto C, Cardone M, Fontana F, et al. The Pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Mol Ther 2009;17:964-71
53. Yu Z, Sawkar AR, Kelly JW. Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J 2007;274:4944-5017
54. Treiber A, Morand O, Clozel M. The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica 2007;37:298-314 (Pubitemid 46439676)
55. Benjamin ER, Flanagan JJ, Schilling A, et al. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. J Inherit Metab Dis 2009;32:424-40
56. Wang X, Koulov AV, Kellner WA, et al. Chemical and biological folding contribute to temperature-sensitive DeltaF508 CFTR trafficking. Traffic 2008;9:1878-93
57. Becq F. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis. Drugs 2010;70:241-59
58. Sanchez-Olle G, Duque J, Egido-Gabas M, et al. Promising results of the chaperone effect caused by iminosugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease. Blood Cell Mol Dis 2009;42:159-66
59. Fan JQ. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 2003;24:355-60
60. Stuzt AE. Iminosugars as glycosidase inhibitors. Wiley-VCH, Weinheim; 1999
61. Compain P, Martin OR. Iminosugars: from synthesis to therapeutic applications. Wiley-VCH, Weinheim; 2008
62. Butters TD. Gaucher disease. Curr Opin Chem Biol 2007;11:412-18 (Pubitemid 47302848)
63. Sawkar AR, Adamski-Werner SL, Cheng WC, et al. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol 2005;12:1235-44 (Pubitemid 41628259)
64. Sawkar AR, Cheng WC, Beutler E, et al. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA 2002;99:15428-33 (Pubitemid 35403951)
65. Kelly JW, Sawkar AR, Beutler E, et al. Chemical chaperones and their effect upon the cellular activity of beta-glucosidase. WO2004037373, 2004
66. Alfonso P, Pampin S, Estrada J, et al. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cell Mol Dis 2005;35:268-76 (Pubitemid 41267059)
67. Yu ZQ, Sawkar AR, Whalen LJ, et al. Isofagomine- and 2,5-anhydro-2,5- imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J Med Chem 2007;50:94-100 (Pubitemid 46105502)
68. Fan J-Q, Ishii S, Asano N. Method for increasing the activity of lysosomal enzymes. US20030119874, 2003
69. Fan J-Q, Ishii S, Asano N. Method for increasing the activity of lysosomal enzymes. US20050113415, 2005
70. Fan J-Q, Ishii S, Asano N. Method for increasing the activity of lysosomal enzymes. US20070021381, 2007
71. Chang HH, Asano N, Ishii S, et al. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients. FEBS J 2006;273:4082-92 (Pubitemid 44253660)
72. Steet RA, Chung S, Wustman B, et al. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc Natl Acad Sci USA 2006;103:13813-18 (Pubitemid 44413990)
73. Steet R, Chung S, Lee W-S, et al. Selective actions of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase. Biochem Pharmacol 2007;73:1376-83 (Pubitemid 46452579)
74. Mugrage B, Tretyakov A. New methods for preparing isofagomine and its derivatives. US2008064559, 2008
75. Mugrage B, Tretyakov A, Fuerst D, et al. New methods for preparing isofagomine and its derivatives. WO2008144773, 2008
76. Mugrage B, Sheth KA, Palling D, Rybcynski PJ. Tartrate salt of isofagomine and methods of use. WO2007140212, 2007
77. Mugrage B, Sheth KA, Palling D, Rybcynski PJ. Tartrate salt of isofagomine and methods of use. US20090176830, 2009
78. Khanna R, Benjamin ER, Pellegrino L, et al. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. FEBS J 2010;277:1618-38
79. Wustman B. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes. WO2006133446, 2006
80. Lockhart D. Treatment of Gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers. WO2008128106, 2008
81. Lockhart D, Wustman B. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones. WO2008134628, 2008
82. Safety study of AT2101 in adult patients with type 1 Gaucher disease currently receiving enzyme replacement therapy. NCT00433147
83. A study to evaluate and characterize the effect of pharmacological chemicals on blood from patients with Gaucher disease. NCT00465062
84. A long-term extension study of AT2101 in type 1 Gaucher patients. NCT00813865
85. A study of oral AT2101 in treatment-na?̈ve patients with Gaucher disease. NCT00446550
86. Amicus Therapeutics. Available from: www.amicustherapeutics.com/ clinicaltrials [Last accessed 11th February 2011]
87. Fan J-Q, Zhu X, Sheth K. Hydroxy piperidine derivatives to treat Gaucher disease. WO2005046612, 2005
88. Fan J-Q, Zhu X, Sheth K. Hydroxy piperidine derivatives to treat Gaucher disease. US20100189708, 2010
89. Boyd R, Lee G. Methods for preventing and/or treating degenerative disorders of the central nervous system. WO2010118282, 2010
90. Boyd R, Lee G. Methods for preventing and/or treating lysosomal storage disorders. WO2010118283, 2010
91. Yu L, Ikeda K, Kato A, et al. alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease. Bioorg Med Chem 2006;14:7736-44 (Pubitemid 44584721)
92. Compain P, Martin OR, Boucheron C, et al. Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher?s disease. ChemBioChem 2006;7:1356-9 (Pubitemid 44369087)
93. Martin OR, Compain P, Boucheron C, Asano N. Novel compounds of the family of iminosugars, uses thereof for treating lysosomal diseases, and methods for preparing same. WO2006136714, 2006
94. Fan JQ, Zhu X, Sheth K. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat Gaucher disease. US20050137223, 2005
95. Fan JQ, Zhu X, Sheth K. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat Gaucher disease. WO2005046611, 2005
96. Diaz-Perez VM, Garcia-Moreno MI, Ortiz Mellet C, et al. Generalized anomeric effect in action: synthesis and evaluation of stable reducing indolizidine glycomimetics as glycosidase inhibitors. J Org Chem 2000;65:136-43
97. Garcia-Moreno MI, Diaz-Perez P, Ortiz Mellet C, Garcia Fernandez JM. Castanospermine-trehazolin hybrids: a new family of glycomimetics with tuneable glycosidase inhibitory properties. Chem Commun 2002:848-9 (Pubitemid 34438184)
98. Garcia-Moreno MI, Diaz-Perez P, Ortiz Mellet C, Garcia Fernandez JM. Synthesis and evaluation of isourea-type glycomimetics related to the indolizidine and trehazolin glycosidase inhibitor families. J Org Chem 2003;68:8890-901 (Pubitemid 37409536)
99. Diaz-Perez P, Garcia-Moreno MI, Ortiz Mellet C, Garcia Fernandez JM. Synthesis and comparative glycosidase inhibitory properties of reducing castanospermine analogues. Eur J Org Chem 2005:2903-13 (Pubitemid 41018407)
100. Aguilar M, Diaz-Perez P, Garcia-Moreno MI, et al. Synthesis and biological evaluation of guanidine-type iminosugars. J Org Chem 2008;73:1995-8 (Pubitemid 351438921)
101. Sanchez-Fernandez E, Risquez-Cuadro R, Aguilar-Moncayo M, et al. Generalized anomeric effect in gem-diamines: stereoselective synthesis of alpha-N-linked disaccharide mimics. Org Lett 2009;11:3306-9
102. Garcia Fernandez JM, Ortiz Mellet C, Garcia Moreno MI, et al. Compounds promoting the activity of mutant glycosidases. WO2010046517, 2010
103. Luan Z, Higaki K, Aguilar-Moncayo M, et al. Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)-deoxynojirimycin. ChemBioChem 2009;10:2780-92
104. Ogawa S, Ashiura M, Uchida C, et al. Synthesis of potent beta-D-glucocerebrosidase inhibitors: N-alkyl-beta-valienamines. Bioorg Med Chem Lett 1996;6:929-32 (Pubitemid 26149936)
105. Lin H, Sugimoto Y, Ohsaki Y, et al. N-Octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease. Biochim Biophys Acta 2004;1689:219-28 (Pubitemid 38981599)
106. Luan Z, Li L, Ninomiya H, et al. The pharmacological chaperone effect of Noctyl- beta-valienamine on human mutant acid beta-glucosidases. Blood Cell Mol Dis 2010;44:48-54
107. Matsuda J, Suzuki O, Oshima A, et al. Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proc Natl Acad Sci USA 2003;100:15912-17 (Pubitemid 38021089)
108. Llebaria Soldevilla A, Casas Brugulat J, Egido Gabas M, et al. Ciclohexano hexasubstituido activador de la enzima beta-glucosidass, procedimiento de sintesis, composicion farmaceutica que lo contiene y sus aplicaciones. EP2289853, 2008
109. Egido-Gabas M, Canals D, Casas J, et al. Aminocyclitols as pharmacological chaperones for glucocerebrosidase, a defective enzyme in Gaucher disease. ChemMedChem 2007;2:992-4
110. Mahuran DJ, Tropak MB, Buttner JD, et al. Method for treating Gaucher disease. WO2009038695, 2009
111. Maegawa GH, Tropak MB, Buttner JD, et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 2009;284:23502-16
112. Maegawa GH, Tropak M, Buttner J, et al. Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J Biol Chem 2007;282:9150-61 (Pubitemid 47093481)
113. Mahuran D, Tropak M, Withers S. Treatment of Tay Sachs or Sandhoff disease by enhancing hexosaminidase activity. WO2004103368, 2004
114. A phase I study of pyrimethamine in patients with GM2 gangliosidosis. NCT00679744
115. Mahuran DJ, Tropak MB, Buttner JD, et al. Compositions and methods for enhancing enzyme activity in Gaucher GM1-gangliosidosis/Morquio B disease and Parkinson?s disease. WO2009049421, 2009
116. Mahuran DJ, Tropak MB, Buttner JD, et al. Compositions and methods for enhancing enzyme activity in Gaucher GM1-gangliosidosis/Morquio B disease and parkinson?s disease. WO2009049422, 2009
117. Futerman A, Sussman JL, Silman I, et al. Gaucher disease drugs and methods to identifying same. US20070166813, 2007
118. Bultron G, Kacena K, Pearson D, et al. The risk of Parkinson?s disease in type 1 Gaucher disease. J Inherit Metab Dis 2010;33:167-73
119. Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep 2010;10:190-8
120. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson?s disease. N Engl J Med 2009;361:1651-61
121. Morello JP, Salahpour A, Laperriere A, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 2000;105:887-95 (Pubitemid 30203061)
122. Amaral MD. Therapy through chaperones: sense or antisense? Cystic fibrosis as a model disease. J Inherit Metab Dis 2006;29:477-87 (Pubitemid 43880653)
123. Barral JM, Broadley SA, Schaffar G, Hartl FU. Roles of molecular chaperones in protein misfolding diseases. Semin Cell Dev Biol 2004;15:17-29 (Pubitemid 38177364)
124. Jones GW, Tuite MF. Chaperoning prions: the cellular machinery for propagating an infectious protein? Bioessays 2005;27:823-32
125. Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 2005;6:11-22 (Pubitemid 40052135)
126. Luan Z, Higaki K, Aguilar-Moncayo M, et al. A fluorescent sp2-iminosugar with pharmacological chaperone activity for Gaucher disease: synthesis and intracellular distribution studies. ChemBioChem 2010;11:2353-64
127. Wang GN, Reinkensmeier G, Zhang SW, et al. Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease. J Med Chem 2009;52:3146-9
128. Kawamura A, Roach AG, Wilson FX, et al. Treatment of protein folding disorders. WO2009066069, 2009
129. Wilson FX, Nash RJ, Horne G, et al. Treatment of lysosomal storage disorders and other proteostatic diseases. WO2010015816, 2010
130. Wilson FX, Storer R, Kawamura A, et al. Drug combination for the treatment of proteostatic diseases. WO2010116141, 2010
131. Witte MD, Kallemeijn WW, Aten J, et al. Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat Chem Biol 2010;6:907-13
132. Kornhaber GJ, Tropak MB, Maegawa GH, et al. Isofagomine induced stabilization of glucocerebrosidase. ChemBioChem 2008;9:2643-9
133. Tropak MB, Kornhaber GJ, Rigat BA, et al. Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/ deuterium exchange mass spectrometry. ChemBioChem 2008;9:2650-62
134. Shen JS, Edwards NJ, Hong YB, Murray GJ. Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase. Biochem Biophys Res Commun 2008;369:1071-5
135. Flanagan JJ, Rossi B, Tang K, et al. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mutat 2009;30:1683-92
136. Marie I. Combined therapy of imiglucerase and miglustat in Gaucher disease with severe bone complications. Press Medicale 2009;38:2S68-70
137. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998;143:1883-98 (Pubitemid 29022611)
138. Mu T-W, Ong DST, Wang Y-J, et al. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 2008;134:769-81